{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:51:35Z","timestamp":1792039895038,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Beyond Air Inc"},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BEYONDAIR21W0"],"award-info":[{"award-number":["BEYONDAIR21W0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beyond Air Inc"},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BEYONDAIR21W0"],"award-info":[{"award-number":["BEYONDAIR21W0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.1513\/annalsats.202407-745rl","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:28:53Z","timestamp":1744111733000},"page":"1092-1097","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":9,"title":["A Pilot Clinical Trial to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous Mycobacteria Lung Infection"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-171X","authenticated-orcid":false,"given":"Rachel M.","family":"Thomson","sequence":"first","affiliation":[{"name":"University of Queensland Brisbane, Queensland, Australia"},{"name":"Greenslopes Private Hospital-Gallipoli Medical Research Clinical Trials Unit Greenslopes, Queensland, Australia"},{"name":"The Prince Charles Hospital Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Burke","sequence":"additional","affiliation":[{"name":"University of Queensland Brisbane, Queensland, Australia"},{"name":"The Prince Charles Hospital Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Macquarie University Hospital Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-2733","authenticated-orcid":false,"given":"Andrew A.","family":"Colin","sequence":"additional","affiliation":[{"name":"Beyond Air, Inc. Garden City, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026012203123458600_bib1","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203123458600_bib2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026012203123458600_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2019.05.001","article-title":"Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan","volume":"152","author":"Furuuchi","year":"2019","journal-title":"Respir Med"},{"key":"2026012203123458600_bib4","doi-asserted-by":"crossref","first-page":"ofac665","DOI":"10.1093\/ofid\/ofac665","article-title":"Changing incidence and characteristics of nontuberculous mycobacterial infections in Scotland and comparison with Mycobacterium tuberculosis complex incidence (2011 to 2019)","volume":"10","author":"Jarchow-MacDonald","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026012203123458600_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large US managed care health plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203123458600_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"2026012203123458600_bib7","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1002\/ppul.24939","article-title":"Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis","volume":"56","author":"Laudone","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026012203123458600_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2026012203123458600_bib9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026012203123458600_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/MCP.0000000000000665","article-title":"Beyond antibiotics for pulmonary nontuberculous mycobacterial disease","volume":"26","author":"Waterer","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"2026012203123458600_bib11","doi-asserted-by":"crossref","first-page":"e0108822","DOI":"10.1128\/spectrum.01088-22","article-title":"Antibiotic maintenance and redevelopment of nontuberculous mycobacteria pulmonary disease after treatment of Mycobacterium avium complex pulmonary disease","volume":"10","author":"Zo","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026012203123458600_bib12","doi-asserted-by":"crossref","first-page":"00574-02020","DOI":"10.1183\/23120541.00574-2020","article-title":"Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics","volume":"7","author":"Faverio","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026012203123458600_bib13","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jfma.2020.05.013","article-title":"Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease","volume":"119","author":"Lan","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"2026012203123458600_bib14","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease","volume":"24","author":"Pennington","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026012203123458600_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12931-022-02299-w","article-title":"Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery","volume":"23","author":"van der Laan","year":"2022","journal-title":"Respir Res"},{"key":"2026012203123458600_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan","year":"2001","journal-title":"Nat Immunol"},{"key":"2026012203123458600_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nrmicro1004","article-title":"Antimicrobial reactive oxygen and nitrogen species: concepts and controversies","volume":"2","author":"Fang","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2026012203123458600_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s15010-016-0879-x","article-title":"Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study","volume":"44","author":"Deppisch","year":"2016","journal-title":"Infection"},{"key":"2026012203123458600_bib19","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.rmed.2022.107069","article-title":"Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection","volume":"206","author":"Flume","year":"2023","journal-title":"Respir Med"},{"key":"2026012203123458600_bib20","doi-asserted-by":"crossref","first-page":"e243979","DOI":"10.1136\/bcr-2021-243979","article-title":"Non-tuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide","volume":"14","author":"Goldbart","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2026012203123458600_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate nitric oxide adjuvant treatment of persistent Mycobacterium infection in cystic fibrosis patients","volume":"37","author":"Yaacoby-Bianu","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2026012203123458600_bib22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203123458600_bib23","doi-asserted-by":"crossref","first-page":"1901300","DOI":"10.1183\/13993003.01300-2019","article-title":"Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease","volume":"55","author":"Henkle","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203123458600_bib24","first-page":"PA2635","article-title":"Development of a quality of life measure for nontuberculous mycobacteria (NTM)","volume":"46","author":"Quittner","year":"2015","journal-title":"Eur Respir J"},{"key":"2026012203123458600_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0300-483X(94)90097-3","article-title":"Overview of nitrogen dioxide effects on the lung with emphasis on military relevance","volume":"89","author":"Mayorga","year":"1994","journal-title":"Toxicology"},{"key":"2026012203123458600_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/j.jvca.2013.02.005","article-title":"Methemoglobinemia: a review and recommendations for management","volume":"28","author":"Cortazzo","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026012203123458600_bib27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0196-0644(99)70167-8","article-title":"Methemoglobinemia: etiology, pharmacology, and clinical management","volume":"34","author":"Wright","year":"1999","journal-title":"Ann Emerg Med"},{"key":"2026012203123458600_bib28","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/ajh.26340","article-title":"Recommendations for diagnosis and treatment of methemoglobinemia","volume":"96","author":"Iolascon","year":"2021","journal-title":"Am J Hematol"},{"key":"2026012203123458600_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1165\/ajrcmb.24.5.4340","article-title":"Nitrogen dioxide induces death in lung epithelial cells in a density-dependent manner","volume":"24","author":"Persinger","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012203123458600_bib30","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3390\/biomedicines10071525","article-title":"High doses of inhaled nitric oxide as an innovative antimicrobial strategy for lung infections","volume":"10","author":"Sorbo","year":"2022","journal-title":"Biomedicines"},{"key":"2026012203123458600_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"},{"key":"2026012203123458600_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2023.02.015","article-title":"Patient-reported symptom and health-related quality-of-life validation and responsiveness during the first 6 months of treatment for Mycobacterium avium complex pulmonary disease","volume":"164","author":"Henkle","year":"2023","journal-title":"Chest"},{"key":"2026012203123458600_bib33","doi-asserted-by":"crossref","first-page":"acmi000154","DOI":"10.1099\/acmi.0.000154","article-title":"Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease","volume":"2","author":"Bogdanovski","year":"2020","journal-title":"Access Microbiol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/7\/1092\/66007456\/annalsats_22_7_1092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/7\/1092\/66007456\/annalsats_22_7_1092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:13:20Z","timestamp":1769069600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/7\/1092\/8381913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202407-745rl","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}